Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization
Spurr, Ian B., Birts, Charles N., Cuda, Francesco, Benkovic, Stephen J., Blaydes, Jeremy P. and Tavassoli, Ali (2012) Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization. ChemBioChem, 13, (11), 1628-1634. (doi:10.1002/cbic.201200279). (PMID:22764122).
Download
Full text not available from this repository.
Description/Abstract
Aminoimidazole carboxamide ribonucleotide transformylase/ inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis. Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å(2) , is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins. Here, we report the development of a small-molecule inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC. The compound is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a K(i) of 17 μM), identified by high-throughput screening. The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analogue of which inhibits AICAR transformylase with a K(i) value of 84 μM. A library of nonnatural analogues of this dipeptide was designed, synthesized, and assayed. The most potent compound inhibits AICAR transformylase with a K(i) value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide. The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line. Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent reduction in cell numbers and cell division rates was observed in cells treated with our ATIC dimerization inhibitor.
| Item Type: | Article |
|---|---|
| ISSNs: | 1439-4227 (print) 1439-7633 (electronic) |
| Keywords: | AICAR transformylase, ATIC, cancer, peptides, protein–protein interaction inhibitors |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Faculty of Medicine > Cancer Sciences Faculty of Natural and Environmental Sciences > Chemistry Faculty of Natural and Environmental Sciences > Chemistry > Chemical Biology Group |
| Item ID: | 341205 |
| Date Deposited: | 23 Jul 2012 10:59 |
| Last Modified: | 26 Apr 2013 06:23 |
| Contributors: | Spurr, Ian B. (Author) Birts, Charles N. (Author) Cuda, Francesco (Author) Benkovic, Stephen J. (Author) Blaydes, Jeremy P. (Author) Tavassoli, Ali (Author) |
| Funder: | Cancer Research UK |
| Date: | 4 July 2012 |
| Status: | Published |
| URI: | http://eprints.soton.ac.uk/id/eprint/341205 |
Actions (login required)
 |
View Item |
